CO6541592A2 - Tiazoles biciclicos como moduladores alostericos de receptores de mglur5 - Google Patents
Tiazoles biciclicos como moduladores alostericos de receptores de mglur5Info
- Publication number
- CO6541592A2 CO6541592A2 CO12101576A CO12101576A CO6541592A2 CO 6541592 A2 CO6541592 A2 CO 6541592A2 CO 12101576 A CO12101576 A CO 12101576A CO 12101576 A CO12101576 A CO 12101576A CO 6541592 A2 CO6541592 A2 CO 6541592A2
- Authority
- CO
- Colombia
- Prior art keywords
- mglur5
- tiazols
- bicycle
- compounds
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Nutrition Science (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a tiazoles bicíclicos novedosos de fórmula (1) que son moduladores alostécos positivos del receptor de glutamato metabotrópico subtipo 5 ( mGluR5 ) y que son útiles para el tratamiento o prevención de trastornos asociados con disfunción de glutamato y enfermedades en los cuales el subtipo mGluR5 de receptores está implicado; la invención también está dirigida a composiciones farmacéuticas que comprenden dichos compuestos, a procedimientos para preparar dichos compuestos y composiciones, y al uso de dichos compuestos y composiciones para la prevención y tratamiento de trastornos en los cuales mGluR5 está implicado.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09179850 | 2009-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6541592A2 true CO6541592A2 (es) | 2012-10-16 |
Family
ID=42112312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12101576A CO6541592A2 (es) | 2009-12-18 | 2012-06-15 | Tiazoles biciclicos como moduladores alostericos de receptores de mglur5 |
Country Status (18)
Country | Link |
---|---|
US (1) | US9174953B2 (es) |
EP (1) | EP2513118B1 (es) |
JP (1) | JP5763673B2 (es) |
KR (1) | KR20120101551A (es) |
CN (1) | CN102666551B (es) |
AU (1) | AU2010332819B2 (es) |
BR (1) | BR112012014235A2 (es) |
CA (1) | CA2782947A1 (es) |
CL (1) | CL2012001606A1 (es) |
CO (1) | CO6541592A2 (es) |
EA (1) | EA020010B1 (es) |
ES (1) | ES2437166T3 (es) |
IL (1) | IL220361A0 (es) |
MX (1) | MX2012007005A (es) |
NZ (1) | NZ600603A (es) |
SG (1) | SG181715A1 (es) |
WO (1) | WO2011073347A1 (es) |
ZA (1) | ZA201204435B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013130639A1 (en) * | 2012-02-29 | 2013-09-06 | Vanderbilt University | Bicyclic oxazole lactams as allosteric modulators of mglur5 receptors |
UA121965C2 (uk) | 2014-01-21 | 2020-08-25 | Янссен Фармацевтика Нв | Комбінації, які містять позитивні алостеричні модулятори або ортостеричні агоністи метаботропного глутаматергічного рецептора 2 підтипу, та їх застосування |
KR102502485B1 (ko) | 2014-01-21 | 2023-02-21 | 얀센 파마슈티카 엔.브이. | 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도 |
CN104262181A (zh) * | 2014-05-14 | 2015-01-07 | 上海应用技术学院 | 一种含氟基团的3-(苯基-1-亚胺)丙酸乙酯类似物的制备方法 |
US10918632B2 (en) | 2016-09-07 | 2021-02-16 | The Children's Hospital Of Philadelphia | Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder |
CN109942600B (zh) * | 2019-04-15 | 2021-08-20 | 内蒙古京东药业有限公司 | 一种依度沙班的制备方法 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2873378B2 (ja) | 1989-08-03 | 1999-03-24 | 株式会社トーキン | 有リード型チップコイル |
ATE127122T1 (de) * | 1990-06-23 | 1995-09-15 | Basf Ag | Dicarbonsäureimide als herbizide. |
US5753664A (en) | 1995-03-16 | 1998-05-19 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
JP2000108513A (ja) | 1998-10-05 | 2000-04-18 | Mitsui Chemicals Inc | 光記録媒体 |
JP2002105085A (ja) | 2000-09-28 | 2002-04-10 | Yamanouchi Pharmaceut Co Ltd | 新規イミダゾチアゾール誘導体 |
US20070060618A1 (en) * | 2002-10-24 | 2007-03-15 | Merck & Co., Inc. | Alkyne derivatives as tracers for metabotropic glutamate receptor binding |
TWI301760B (en) | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
MX2007007227A (es) | 2004-12-17 | 2007-08-21 | Lilly Co Eli | Derivados de tiazolopiridinona como antagonistas del receptor mch. |
CA2593439C (en) | 2005-01-14 | 2014-02-25 | F. Hoffmann-La Roche Ag | Thiazole-4-carboxamide derivatives as mglur5 antagonists |
EP1910350A1 (en) | 2005-07-09 | 2008-04-16 | AstraZeneca AB | 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes |
WO2007023242A1 (en) * | 2005-08-24 | 2007-03-01 | Merz Pharma Gmbh & Co. Kgaa | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors |
CN101304983A (zh) | 2005-11-07 | 2008-11-12 | Irm责任有限公司 | 作为ppar调节剂的化合物和组合物 |
KR101020431B1 (ko) * | 2005-11-08 | 2011-03-08 | 에프. 호프만-라 로슈 아게 | mGluR5 수용체 길항제로서의 티아졸로[4,5-c]피리딘 유도체 |
DE102006011574A1 (de) | 2006-03-10 | 2007-10-31 | Grünenthal GmbH | Substituierte Imidazo[2,1-b]thiazol-Verbindungen und ihre Verwendung zur Herstellung von Arzneimitteln |
ATE510840T1 (de) * | 2006-06-26 | 2011-06-15 | Ucb Pharma Sa | Kondensierte thiazol-derivate als kinasehemmer |
EP2049548A1 (en) | 2006-07-27 | 2009-04-22 | UCB Pharma, S.A. | Fused oxazoles & thiazoles as histamine h3- receptor ligands |
GB0622202D0 (en) | 2006-11-07 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel compounds |
EP2094712B1 (en) | 2006-11-15 | 2011-10-12 | Vertex Pharmceuticals Incorporated | Compounds useful as protein kinase inhibitors |
JP4714669B2 (ja) | 2006-12-01 | 2011-06-29 | 日本化薬株式会社 | ヘッダーアッシー、スクイブならびにエアバッグ用ガス発生装置およびシートベルトプリテンショナー用ガス発生装置 |
CA2671765A1 (en) | 2006-12-14 | 2008-06-26 | Eli Lilly And Company | 5- [4- (azetidin-3-yloxy) -phenyl] -2-phenyl-5h-thiazolo [5,4-c] pyridin-4-one derivatives and their use as mch receptor |
NZ581817A (en) | 2007-06-03 | 2012-05-25 | Univ Vanderbilt | Benzamide mglur5 positive allosteric modulators and methods of making and using same |
AU2008345225A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
JP5651681B2 (ja) | 2009-04-03 | 2015-01-14 | 大日本住友製薬株式会社 | 代謝型グルタミン酸受容体5介在障害の治療のための化合物、およびその使用方法 |
BR112012014729A2 (pt) | 2009-12-18 | 2016-03-29 | Boehringer Ingelheim Int | terapia combinada contra hcv |
US9040707B2 (en) | 2009-12-18 | 2015-05-26 | Janssen Pharmaceutica Nv | Bicyclic thiazoles as allosteric modulators of mGluR5 receptors |
-
2010
- 2010-12-16 AU AU2010332819A patent/AU2010332819B2/en not_active Ceased
- 2010-12-16 EP EP10790989.7A patent/EP2513118B1/en active Active
- 2010-12-16 ES ES10790989.7T patent/ES2437166T3/es active Active
- 2010-12-16 US US13/516,968 patent/US9174953B2/en not_active Expired - Fee Related
- 2010-12-16 JP JP2012543767A patent/JP5763673B2/ja not_active Expired - Fee Related
- 2010-12-16 EA EA201290534A patent/EA020010B1/ru not_active IP Right Cessation
- 2010-12-16 CA CA2782947A patent/CA2782947A1/en not_active Abandoned
- 2010-12-16 WO PCT/EP2010/069972 patent/WO2011073347A1/en active Application Filing
- 2010-12-16 KR KR1020127018643A patent/KR20120101551A/ko not_active Application Discontinuation
- 2010-12-16 CN CN201080057656.7A patent/CN102666551B/zh not_active Expired - Fee Related
- 2010-12-16 SG SG2012044053A patent/SG181715A1/en unknown
- 2010-12-16 NZ NZ600603A patent/NZ600603A/xx not_active IP Right Cessation
- 2010-12-16 MX MX2012007005A patent/MX2012007005A/es active IP Right Grant
- 2010-12-16 BR BR112012014235A patent/BR112012014235A2/pt not_active IP Right Cessation
-
2012
- 2012-06-13 IL IL220361A patent/IL220361A0/en unknown
- 2012-06-14 CL CL2012001606A patent/CL2012001606A1/es unknown
- 2012-06-15 ZA ZA2012/04435A patent/ZA201204435B/en unknown
- 2012-06-15 CO CO12101576A patent/CO6541592A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20120252800A1 (en) | 2012-10-04 |
IL220361A0 (en) | 2012-08-30 |
MX2012007005A (es) | 2012-07-03 |
BR112012014235A2 (pt) | 2016-06-14 |
ZA201204435B (en) | 2014-11-26 |
CL2012001606A1 (es) | 2012-10-05 |
EA201290534A1 (ru) | 2012-11-30 |
US9174953B2 (en) | 2015-11-03 |
CN102666551A (zh) | 2012-09-12 |
EP2513118B1 (en) | 2013-09-18 |
SG181715A1 (en) | 2012-07-30 |
KR20120101551A (ko) | 2012-09-13 |
EA020010B1 (ru) | 2014-07-30 |
CA2782947A1 (en) | 2011-06-23 |
CN102666551B (zh) | 2014-12-10 |
EP2513118A1 (en) | 2012-10-24 |
JP2013514327A (ja) | 2013-04-25 |
ES2437166T3 (es) | 2014-01-09 |
JP5763673B2 (ja) | 2015-08-12 |
AU2010332819A1 (en) | 2012-06-21 |
WO2011073347A1 (en) | 2011-06-23 |
NZ600603A (en) | 2013-07-26 |
AU2010332819B2 (en) | 2014-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32996A (es) | Antagonistas del receptor crth2 basados en indol | |
GT201300122A (es) | Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano | |
CR20150296A (es) | Novedosos derivados de bencimidazol como antagonistas de ep4 | |
MX2011005242A (es) | Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos. | |
ECSP11011019A (es) | Antagonistas del receptor de orexina de isonicotinamida | |
CR10922A (es) | Derivados de indol como antagonistas receptores de s1p1 | |
ECSP066856A (es) | Compuestos novedosos como moduladores del receptor opioide | |
HN2010001563A (es) | Compuestos | |
GT201200201A (es) | Moduladores alostéricos positivos de receptores m1 de la quinolina amida | |
CL2011002837A1 (es) | Compuestos derivados de 1,2,4-triazolo[4,3-a]piridina, moduladores alostericos positivos de receptores mglur2; composicion farmaceutica; proceso para prepararla; y su uso en el tratamiento o la prevencion de un trastorno del sistema nervioso central tal como la ansiedad, esquizofrenia y migraña, entre otros. | |
CL2013003527A1 (es) | Compuestos heterociclicos antagonistas de los receptores muscarinicos y agonistas del receptor beta2 adrenergico; su composicion farmaceutica; su combinacion; un dispositivo y su uso en la prevencion y/o el tratamiento de enfermedades bronco-obstructivas o inflamatorias como asma y epoc. | |
UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
CO6541592A2 (es) | Tiazoles biciclicos como moduladores alostericos de receptores de mglur5 | |
CR10243A (es) | "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos" | |
UY32426A (es) | Derivados bicilicos para uso en el tratamiento de enfermedades relacionadas al receptor de androgeno | |
EA201190017A1 (ru) | Аминоэфирные производные алкалоидов и их медицинские композиции | |
MX353209B (es) | Antagonistas d2, metodos de sintesis y metodos de uso. | |
CO6531479A2 (es) | Derivados de espirolactama y uso de los mismos | |
EA201291327A1 (ru) | Замещенные 6-метилникотинамиды как позитивные аллостерические модуляторы mglur5 | |
CO6300937A2 (es) | Derivados de 3-carboxipropil-aminotetralina y compuestos relacionados como antagonistas de receptores opioides mu | |
PH12016500312A1 (en) | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | |
ATE546448T1 (de) | Urotensin-ii-rezeptorantagonisten | |
CO6541615A2 (es) | Tiazoles bicíclicos como moduladores alostéricos de receptores mglur5 | |
WO2012061019A3 (en) | Tricyclic mglur5 receptor modulators | |
CL2012000102A1 (es) | Compuestos derivados de (fenil/piridin)-etinil-imidazol, antagonistas del los receptores metabotropicos de glutamato (mglur5); procedimiento de preparacion; y su uso para el tratamiento y prevencion del alzheimer, demencia senil, parkinson, entre otras. |